Health
Servier India introduces‘Ivosidenib’ (Tibsovo®),in India, First-in-classTargetedTherapy in Oncologyfor Rare IDH1-Mutated AML and Cholangiocarcinoma
2025-Servier India, a subsidiary of the leading French pharmaceutical Servier Group, announced the launch ofIvosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma,with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO)…
Consumer Choice Center Advocates for Significant Revisions to WHO Governance and Operations Amidst Approval of Increased Mandatory Membership
India, 2025: The World Health Organization (WHO) is facing intense scrutiny following the approval of a 20% increase in mandatory membership dues, amounting to an additional $120 million per year extracted directly from taxpayers worldwide. The Consumer Choice Center joins critics in questioning whether the organization truly deserves this financial boost, citing significant issues with…
Serum Institute of India Launches Nationwide HPV-Cancer Public Awareness Campaign
Medical Experts Join Forces in Ahmedabad to Tackle HPV Associated Cancers National, 31 May, 2025: The “Conquer HPV & Cancer Conclave 2025” was launched today in Ahmedabad as part of a nationwide public health initiative led by the Serum Institute of India (SII). India continues to face a significant burden of HPV-related diseases, particularly cervical…